
Big Pharma as Good Guys ...
(Mar 13, 2009)The established pharma industry (by which I mean the profitable and sustainably cash generative companies) may appear to be less troubled than most industries by the fallout from the recession but one
(Mar 13, 2009)Allusions to Darwin can be fun and I suppose corporate archaeologists of the next geological era will happily sift through the promotional detritus of yesteryear (Lucites, mugs, pens etc) as the only
(Mar 20, 2009)I can understand the frustration with lack of reliable CRM data but the solution is not to abandon analytics but to change the incentives for field force data capture.
(Mar 24, 2009)Phil Taylor reports on the commercial and scientific opportunities facing medical scientific liaisons (MSLs)
Andrew Tolve investigates the opportunities and challenges for pharma’s use of cloud computing
Phil Taylor explores how pharma’s relationship to key opinion leaders is changing - for the better
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs